A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
-
BUSINESS Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
-
BUSINESS Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
-
REGULATORY Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
-
REGULATORY Chuikyo Reps Fret Negative Impact of Tougher Pledge Rule, but MHLW Says It’s Conducive to Stable Supplies
July 26, 2021
-
REGULATORY MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
-
REGULATORY Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
-
REGULATORY Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
-
REGULATORY Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
-
REGULATORY Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
-
BUSINESS Arcalis Sees Opportunities in mRNA Drugs, Eyes Tens of Billions of Yen in CDMO Sales
July 19, 2021
-
REGULATORY New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
-
REGULATORY Japan to Lower Moderna Vaccine’s Minimum Age to 12
July 16, 2021
-
BUSINESS Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
-
BUSINESS Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too
July 14, 2021
-
REGULATORY Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
-
COMMENTARY Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
-
ACADEMIA Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
-
BUSINESS Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
July 9, 2021
-
BUSINESS FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s
July 9, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…